SCPH Insider Trading

Insider Ownership Percentage: 5.52%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

scPharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at scPharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$4M-$2M$0$2M$4MTotal Insider BuyingTotal Insider Selling

scPharmaceuticals Share Price & Price History

Current Price: $2.32
Price Change: Price Increase of +0.02 (0.87%)
As of 04/4/2025 05:00 PM ET

This chart shows the closing price history over time for SCPH up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$2.32Closing price on 04/05/25:

scPharmaceuticals Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for scPharmaceuticals (NASDAQ:SCPH)

89.52% of scPharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at SCPH by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$5.66Mbought$2.07MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10M$0$10MTotal InflowsTotal Outflows
scPharmaceuticals logo
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
Read More on scPharmaceuticals

Today's Range

Now: $2.32
Low: $2.21
High: $2.37

50 Day Range

MA: $3.15
Low: $2.30
High: $3.68

52 Week Range

Now: $2.32
Low: $2.20
High: $5.65

Volume

570,812 shs

Average Volume

342,515 shs

Market Capitalization

$116.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.38